GSK/Yamanouchi Vesicare Joint Venture Unaffected By Fujisawa Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline does not expect its Vesicare joint venture with Yamanouchi to be affected by the merger between Yamanouchi and Fujisawa
You may also be interested in...
GSK New Product Launches In 2004 Will Include Vesicare, Avandaryl
GlaxoSmithKline expects that Vesicare and Avandaryl will be approved before the end of the year, the company said Sept. 14 at the Bear Stearns health care conference in New York
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.